Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Total Current Liabilities (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 5 years of Total Current Liabilities data on record, last reported at $160.4 million in Q3 2025.

  • For Q3 2025, Total Current Liabilities changed N/A year-over-year to $160.4 million; the TTM value through Sep 2025 reached $160.4 million, changed N/A, while the annual FY2023 figure was $87.1 million, 34.51% up from the prior year.
  • Total Current Liabilities reached $160.4 million in Q3 2025 per MIRM's latest filing, up from $144.8 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $160.4 million in Q3 2025 and bottomed at $29.0 million in Q2 2021.
  • Average Total Current Liabilities over 4 years is $66.2 million, with a median of $50.9 million recorded in 2021.
  • Peak YoY movement for Total Current Liabilities: surged 168.13% in 2021, then dropped 1.34% in 2022.
  • A 4-year view of Total Current Liabilities shows it stood at $42.6 million in 2021, then surged by 51.96% to $64.7 million in 2022, then surged by 34.51% to $87.1 million in 2023, then soared by 84.19% to $160.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $160.4 million in Q3 2025, $144.8 million in Q2 2025, and $87.1 million in Q4 2023.